HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Barone, P. Search for Related Content PubMed PubMed Citation Articles by Barone, P.

Neurology supplements are not peer-reviewed. Information contained in Neurology supplements represent the opinions of the authors and are not endorsed by nor do they reflect the views of the American Academy of Neurology, Editor-in-Chief, or Associate Editors of Neurology.

Clinical strategies to prevent and delay motor complications

From the Department of Neurological Sciences, University Federico II, Naples, Italy.

Address correspondence and reprint requests to Prof. Paolo Barone, Department of Neurological Sciences, University of Naples Federico II, Via Pansini 5, 80131 Napoli, Italy.

Current evidence suggests that motor complications associated with long-term L-dopa treatment in patients with Parkinson’s disease (PD) are the consequence of two factors: the disease course, with progressive destruction of dopaminergic terminals, and the pulsatile nonphysiologic stimulation of dopamine receptors caused by multiple administrations of L-dopa. Pharmacokinetic considerations suggest that continuous dopaminergic stimulation (CDS) may be achieved either by using long-acting dopamine agonists (DAs) or by continuously delivering L-dopa. A variety of therapeutic strategies based on CDS have been proposed to reduce motor complications that occur after long-term L-dopa treatment. Several recent studies have suggested the possibility of preventing motor complications by initiating treatment with DAs, including pramipexole, cabergoline, and ropinirole. Such a preventive effect may be due to the CDS provided by the agonists. In addition, new experimental evidence suggests that initial treatment with pramipexole compared with L-dopa not only reduces the 4-year risk of developing motor complications but also is associated with less loss of dopaminergic terminals, as assessed by SPECT. These data highlight the critical role of DAs in the treatment of PD. Compared with L-dopa, these drugs provide a more physiologic stimulation of dopaminergic receptors and, in the case of pramipexole and ropinirole, may contribute to sparing of dopaminergic terminals, thus affecting both factors responsible for the development of motor complications.

This article has been cited by other articles:

				R. L. Watts, J. Jankovic, C. Waters, A. Rajput, B. Boroojerdi, and J. Rao Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease Neurology, January 23, 2007; 68(4): 272 - 276. [Abstract] [Full Text] [PDF]

				Q.-Y. Huang, C. Wei, L. Yu, J. E. Coelho, H.-Y. Shen, A. Kalda, J. Linden, and J.-F. Chen Adenosine A2A Receptors in Bone Marrow-Derived Cells But Not in Forebrain Neurons Are Important Contributors to 3-Nitropropionic Acid-Induced Striatal Damage as Revealed by Cell-Type-Selective Inactivation. J. Neurosci., November 1, 2006; 26(44): 11371 - 11378. [Abstract] [Full Text] [PDF]

				F. Ciruela, V. Casado, R. J. Rodrigues, R. Lujan, J. Burgueno, M. Canals, J. Borycz, N. Rebola, S. R. Goldberg, J. Mallol, et al. Presynaptic Control of Striatal Glutamatergic Neurotransmission by Adenosine A1-A2A Receptor Heteromers J. Neurosci., February 15, 2006; 26(7): 2080 - 2087. [Abstract] [Full Text] [PDF]

				J. A. Van Gerpen, N. Kumar, J. H. Bower, S. Weigand, and J. E. Ahlskog Levodopa-Associated Dyskinesia Risk Among Parkinson Disease Patients in Olmsted County, Minnesota, 1976-1990 Arch Neurol, February 1, 2006; 63(2): 205 - 209. [Abstract] [Full Text] [PDF]